Latest Breaking News On - Coherus biosciences inc - Page 1 : comparemela.com

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Jami-taylor
Nasdaq
Coherus-biosciences-inc
Global-healthcare
Global-healthcare-conference
Daylight-time
Investor-events
Contact-information

Coherus BioSciences (NASDAQ:CHRS) Given "Buy" Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $12.00 price target on the biotechnology company’s stock. Separately, Truist Financial cut their price target on shares of Coherus BioSciences from $8.00 to $7.00 […]

United-states
Coherus-biosciences
Barclays-plc
Vanguard-group-inc
Coherus-biosciences-company-profile
Rafferty-asset-management
Coherus-biosciences-inc
Brandywine-global-investment-management
Cm-management
Nasdaq
Free-report
Truist-financial

Coherus BioSciences (NASDAQ:CHRS) Receives Buy Rating from HC Wainwright

Coherus BioSciences (NASDAQ:CHRS) Receives Buy Rating from HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Los-angeles
California
United-states
Texas
Coherus-biosciences
Coherus-biosciences-company-profile
Barclays-plc
Mirae-asset-global-investments-co
Coherus-biosciences-inc
Los-angeles-capital-management
Free-report
Truist-financial

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 Antibody, CHS-114, at the 2024 American Society of Clinical Oncology Annual Meeting

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 Antibody, CHS-114, at the 2024 American Society of Clinical Oncology Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Mccormick-place
Illinois
United-states
Chicago
Coherus-biosciences-inc
Coherus-biosciences

Coherus Presents Preliminary Results from Phase I Dose

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective.

Chicago
Illinois
United-states
Mccormick-place
Rosh-dias
Jodi-sievers
Coherus-biosciences
Jami-taylor
Corporate-communications
Nasdaq
Abbvie-inc
Exchange-commission